Review

ezh2 inhibitor gsk 126 (MedChemExpress)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress ezh2 inhibitor gsk 126
Ezh2 Inhibitor Gsk 126, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 141 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ezh2+inhibitor+gsk+126/GSK126/pm41760656-225-25-28
Average 97 stars, based on 141 article reviews

ezh2 inhibitor gsk 126 - by Bioz Stars, 2026-09

97/100 stars

Images

Concentration Assay:

Article Title: A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state
Article Snippet: The TGF-β inhibitor A83-01 (Tocris) was dissolved in DMSO at 1 mM and used at a concentration of 0.5 μM; an equivalent amount of DMSO was added to control cultures. .. The EZH2 inhibitor GSK-126 (MedChemExpress) was dissolved in DMSO at 10 mM and used at a concentration of 10 μM. ..

Article Title: Immunotherapy with lymphocytes derived from banked tumor tissue in two refractory NSCLC patients with leptomeningeal metastases: a report of two cases
Article Snippet: .. Tregs were isolated from TILs using a regulatory T cell isolation kit (Miltenyi Biotec 130094-775, Bergisch Gladbach, Germany) according to the manufacturer’s instructions and treated with EZH2 inhibitor GSK 126 (MedChemExpress, China) at the concentration of 2 μM before pooling and infusion back to patients. .. TILs were further expanded in log phase for an additional week followed by rapid expanding in REP medium supplemented with 15% serum replacement, 3000 IU/mL recombinant human IL-2, 30 ng/mL anti-CD3 (humanized OKT3, 10977-H001, Sino Biological Inc., China), and the same additives described above in the presence of lethally irradiated (45 Gy) allogeneic PBMCs at a feeder cell/TIL ratio of 100:1.

Article Title: A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state.
Article Snippet: The TGF-β inhibitor A83-01 (Tocris) was dissolved in DMSO at 1 mM and used at a concentration of 0.5 μM; an equivalent amount of DMSO was added to control cultures. .. The EZH2 inhibitor GSK-126 (MedChemExpress) was dissolved in DMSO at 10 mM and used at a concentration of 10 μM. ..

Isolation:

Cell Isolation:

Methylation:

Article Title: Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis.
Article Snippet: .. For modulating the epigenome (by targeting H3K27 methylation), 4-week-old mice were treated intraperitoneally 3 times per week during 5 weeks with 50 mg/kg of the EZH2 inhibitor GSK-126 (MedChemExpress, HY-13470-50 MG) or the KDM6 inhibitor GSK-J4 (MedChemExpress, HY-15648B-50 MG) dissolved in DMSO/Captisol® (Selleck Chemicals, S4592-5G). .. Mammary tumors were induced by MPA and 7,12- dimethylbenzanthracene (DMBA) (Fisher Scientific #408181000) as described in 14,24.

Image Search Results

(A) Cell Viability (MTT) assay at different concentrations of CDDP for 24h in OS cells. (B) Change in mRNA expression of EZH2 at 24h when exposed to a sub-lethal dose of CDDP (3 µM). (C) Immunoblot analysis showing expression of EZH2 at 24h; GAPDH served as the loading control. (D) Immunofluorescence staining showing the expression of EZH2 at 24h (Scale Bar: 20 μm). (E) Immunoblot analysis showing expression of H3K27me3 at 24h; total H3 served as the loading control. (F) Immunofluorescence staining showing the expression of H3K27me3 at 24h (Scale Bar: 20 μm). All values are represented as mean±SD; n=3. Unpaired t-test was applied with (*) p<0.05 to estimate the significance when two groups were compared. CTRL represents untreated cells.

Journal: bioRxiv

Article Title: Cisplatin-induced oxidative stress regulates YAP to modulate epigenome promoting survival of osteosarcoma cells

doi: 10.1101/2025.08.25.672065

Figure Lengend Snippet: (A) Cell Viability (MTT) assay at different concentrations of CDDP for 24h in OS cells. (B) Change in mRNA expression of EZH2 at 24h when exposed to a sub-lethal dose of CDDP (3 µM). (C) Immunoblot analysis showing expression of EZH2 at 24h; GAPDH served as the loading control. (D) Immunofluorescence staining showing the expression of EZH2 at 24h (Scale Bar: 20 μm). (E) Immunoblot analysis showing expression of H3K27me3 at 24h; total H3 served as the loading control. (F) Immunofluorescence staining showing the expression of H3K27me3 at 24h (Scale Bar: 20 μm). All values are represented as mean±SD; n=3. Unpaired t-test was applied with (*) p<0.05 to estimate the significance when two groups were compared. CTRL represents untreated cells.

Article Snippet: Suberoylanilide hydroxamic acid (SAHA; #H1388) was purchased from TCI, and the EZH2 inhibitor GSK-126 (#5005800001) from Merck.

Techniques: MTT Assay, Expressing, Western Blot, Control, Immunofluorescence, Staining

(A) Reactive Oxygen species levels after incubating cells with CDDP for various time points (24h, 48h, 72h) as measured through DCFDA staining. (B) Flow cytometric analysis of mitochondrial ROS generation via MitoSox at 24h. (C) Immunoblot analysis showing expression of EZH2 after removal of oxidative stress (with NAC) at 24h; GAPDH is the loading control. (D) Immunofluorescence staining showing the expression of EZH2 at 24h (Scale Bar: 20 μm). (E) Immunoblot analysis showing expression of H3K27me3 after removal of oxidative stress (with NAC) at 24h; total H3 is the loading control. (F) Immunofluorescence staining showing the expression of H3K27me3 at 24h (Scale Bar: 20 μm). (G) Change in mRNA expression of cell cycle gene CCNA2 at 24h. (H) Enrichment of H3K27me3 over the cell cycle genes (CCNA2) as analyzed through ChIP-qPCR. All values are represented as mean±SD; n=3. Unpaired t-test and One-way ANOVA, wherever applicable, were applied with (*) p<0.05 to estimate the significance when two groups were compared. CTRL represents untreated cells.

Journal: bioRxiv

Article Title: Cisplatin-induced oxidative stress regulates YAP to modulate epigenome promoting survival of osteosarcoma cells

doi: 10.1101/2025.08.25.672065

Figure Lengend Snippet: (A) Reactive Oxygen species levels after incubating cells with CDDP for various time points (24h, 48h, 72h) as measured through DCFDA staining. (B) Flow cytometric analysis of mitochondrial ROS generation via MitoSox at 24h. (C) Immunoblot analysis showing expression of EZH2 after removal of oxidative stress (with NAC) at 24h; GAPDH is the loading control. (D) Immunofluorescence staining showing the expression of EZH2 at 24h (Scale Bar: 20 μm). (E) Immunoblot analysis showing expression of H3K27me3 after removal of oxidative stress (with NAC) at 24h; total H3 is the loading control. (F) Immunofluorescence staining showing the expression of H3K27me3 at 24h (Scale Bar: 20 μm). (G) Change in mRNA expression of cell cycle gene CCNA2 at 24h. (H) Enrichment of H3K27me3 over the cell cycle genes (CCNA2) as analyzed through ChIP-qPCR. All values are represented as mean±SD; n=3. Unpaired t-test and One-way ANOVA, wherever applicable, were applied with (*) p<0.05 to estimate the significance when two groups were compared. CTRL represents untreated cells.

Article Snippet: Suberoylanilide hydroxamic acid (SAHA; #H1388) was purchased from TCI, and the EZH2 inhibitor GSK-126 (#5005800001) from Merck.

Techniques: Staining, Western Blot, Expressing, Control, Immunofluorescence, ChIP-qPCR

(A) Change in H3K27me3 expression through immunoblot post CDDP plus VP (10 μM) treatment. (B) Immunoblot analysis showing expression of H3K27me3 after siRNA-mediated knockdown of YAP 24h post CDDP exposure; GAPDH is the loading control. (C) Change in mRNA and protein expression of EZH2 at 24h when YAP is inhibited with VP (10 µM) or (D) after siRNA treatment (40 nm), respectively; GAPDH is the loading control. (E) Immunofluorescence staining showing the expression of EZH2 at 24h (Scale Bar: 20 μm) when YAP is ablated via VP or siRNA. (F) Immunofluorescence staining showing the expression and co-localization of YAP and EZH2 at 24h with CDDP, and CDDP plus VP (10 µM) (Scale Bar: 20 μm). (G) Immunoblot analysis showing physical interaction between EZH2 and YAP at 24h, after CDDP exposure. All values are represented as mean±SD; n=3. *, ** and *** refers to p value significance of ≤0.01, ≤0.001 & ≤0.0001 respectively.

Journal: bioRxiv

Article Title: Cisplatin-induced oxidative stress regulates YAP to modulate epigenome promoting survival of osteosarcoma cells

doi: 10.1101/2025.08.25.672065

Figure Lengend Snippet: (A) Change in H3K27me3 expression through immunoblot post CDDP plus VP (10 μM) treatment. (B) Immunoblot analysis showing expression of H3K27me3 after siRNA-mediated knockdown of YAP 24h post CDDP exposure; GAPDH is the loading control. (C) Change in mRNA and protein expression of EZH2 at 24h when YAP is inhibited with VP (10 µM) or (D) after siRNA treatment (40 nm), respectively; GAPDH is the loading control. (E) Immunofluorescence staining showing the expression of EZH2 at 24h (Scale Bar: 20 μm) when YAP is ablated via VP or siRNA. (F) Immunofluorescence staining showing the expression and co-localization of YAP and EZH2 at 24h with CDDP, and CDDP plus VP (10 µM) (Scale Bar: 20 μm). (G) Immunoblot analysis showing physical interaction between EZH2 and YAP at 24h, after CDDP exposure. All values are represented as mean±SD; n=3. *, ** and *** refers to p value significance of ≤0.01, ≤0.001 & ≤0.0001 respectively.

Article Snippet: Suberoylanilide hydroxamic acid (SAHA; #H1388) was purchased from TCI, and the EZH2 inhibitor GSK-126 (#5005800001) from Merck.

Techniques: Expressing, Western Blot, Knockdown, Control, Immunofluorescence, Staining

(A) Cell Viability (MTT) assay at different concentrations of VP and CDDP (3 µM) for 24h. (B) The bar graph illustrates the number of Annexin V-positive cells in CDDP plus VP (10 µM), compared to only CDDP-treated cells. (C) Cell Viability (MTT) assay at different concentrations of GSK-126 and CDDP (3 µM) for 24h. (D) The bar graph illustrates the number of Annexin-V positive cells in CDDP plus GSK-126 (25 µM), compared to only CDDP-treated cells. (E) Change in H3K27me3 expression through immunoblot post CDDP plus SAHA (15 µM) treatment. (F) Immunoblot analysis showing expression of EZH2 after combined treatment of CDDP (3 µM) plus SAHA (15 µM) at 24h; GAPDH is the loading control. (G) Cell Viability (MTT) assay at different concentrations of SAHA and CDDP (3 µM) for 24h. (H) Bar graph illustrating the number of Annexin-V positive cells in CDDP plus SAHA (15 µM), compared to only CDDP-treated cells. All values are represented as mean±SD; n=3. *, **, ***refers to p value significance of ≤0.01, ≤0.001 & ≤0.0001 respectively. CTRL represents the untreated cells.

Journal: bioRxiv

Article Title: Cisplatin-induced oxidative stress regulates YAP to modulate epigenome promoting survival of osteosarcoma cells

doi: 10.1101/2025.08.25.672065

Figure Lengend Snippet: (A) Cell Viability (MTT) assay at different concentrations of VP and CDDP (3 µM) for 24h. (B) The bar graph illustrates the number of Annexin V-positive cells in CDDP plus VP (10 µM), compared to only CDDP-treated cells. (C) Cell Viability (MTT) assay at different concentrations of GSK-126 and CDDP (3 µM) for 24h. (D) The bar graph illustrates the number of Annexin-V positive cells in CDDP plus GSK-126 (25 µM), compared to only CDDP-treated cells. (E) Change in H3K27me3 expression through immunoblot post CDDP plus SAHA (15 µM) treatment. (F) Immunoblot analysis showing expression of EZH2 after combined treatment of CDDP (3 µM) plus SAHA (15 µM) at 24h; GAPDH is the loading control. (G) Cell Viability (MTT) assay at different concentrations of SAHA and CDDP (3 µM) for 24h. (H) Bar graph illustrating the number of Annexin-V positive cells in CDDP plus SAHA (15 µM), compared to only CDDP-treated cells. All values are represented as mean±SD; n=3. *, **, ***refers to p value significance of ≤0.01, ≤0.001 & ≤0.0001 respectively. CTRL represents the untreated cells.

Article Snippet: Suberoylanilide hydroxamic acid (SAHA; #H1388) was purchased from TCI, and the EZH2 inhibitor GSK-126 (#5005800001) from Merck.

Techniques: MTT Assay, Expressing, Western Blot, Control

(A) Relative expression of the Nkx2-9 transcript after 4 d of control (DMSO) or EZH2 inhibition with GSK126 (n = 4, mean ± s.e.m.). (B, C) Chromatin Immunoprecipitations against (B) H3K27me3 enrichment and (C) H2AK119ub enrichment in cells treated with the EZH2 inhibitor GSK126. Data are presented as bound/input either no recruitment or recruitment (n = 2 mean ± s.e.m.). (D) Fold change in the expression of Nxk2-9 under various treatment conditions: 24 h cBAF recruitment, 24 h gBAF recruitment, 24 h pBAF recruitment, constant (>5 d CRISPR-VP64 activation) or 4 d of EZH2 inhibition (n = 4, mean ± s.e.m.).

Journal: Life Science Alliance

Article Title: Differential modulation of polycomb-associated histone marks by cBAF, pBAF, and gBAF complexes

doi: 10.26508/lsa.202402715

Figure Lengend Snippet: (A) Relative expression of the Nkx2-9 transcript after 4 d of control (DMSO) or EZH2 inhibition with GSK126 (n = 4, mean ± s.e.m.). (B, C) Chromatin Immunoprecipitations against (B) H3K27me3 enrichment and (C) H2AK119ub enrichment in cells treated with the EZH2 inhibitor GSK126. Data are presented as bound/input either no recruitment or recruitment (n = 2 mean ± s.e.m.). (D) Fold change in the expression of Nxk2-9 under various treatment conditions: 24 h cBAF recruitment, 24 h gBAF recruitment, 24 h pBAF recruitment, constant (>5 d CRISPR-VP64 activation) or 4 d of EZH2 inhibition (n = 4, mean ± s.e.m.).

Article Snippet: To inhibit the polycomb repressive complex 2 protein, we used a specific chemical inhibitor to EZH2 called GSK126 (Cat. No. 6790; Tocris).

Techniques: Expressing, Control, Inhibition, CRISPR, Activation Assay

(A) RT-qPCR of the fold change of Nkx2-9 transcription (normalized to Ywhaz1 ) after recruitment of cBAF, gBAF, and pBAF. (n = 4; mean ± s.e.m.). Significance was evaluated by a one-sample t test (null = 1.0) corrected for multiple samples ** denotes q < 0.01 (B) Western blot against H3K27me3, pan H3 (loading control), or H2AK119ub after 0, 2, or 4 d of treatment with DMSO control or EZH2 inhibitor GSK126 (3 μM). (C) Fold change in Nkx2-9 transcript levels by RT-qPCR after 4 d of EZH2 inhibition compared with DMSO control (n = 4, mean ± s.e.m.). Significance was evaluated by a one-sample t test (null = 1.0). Source data are available for this figure.

Journal: Life Science Alliance

Article Title: Differential modulation of polycomb-associated histone marks by cBAF, pBAF, and gBAF complexes

doi: 10.26508/lsa.202402715

Figure Lengend Snippet: (A) RT-qPCR of the fold change of Nkx2-9 transcription (normalized to Ywhaz1 ) after recruitment of cBAF, gBAF, and pBAF. (n = 4; mean ± s.e.m.). Significance was evaluated by a one-sample t test (null = 1.0) corrected for multiple samples ** denotes q < 0.01 (B) Western blot against H3K27me3, pan H3 (loading control), or H2AK119ub after 0, 2, or 4 d of treatment with DMSO control or EZH2 inhibitor GSK126 (3 μM). (C) Fold change in Nkx2-9 transcript levels by RT-qPCR after 4 d of EZH2 inhibition compared with DMSO control (n = 4, mean ± s.e.m.). Significance was evaluated by a one-sample t test (null = 1.0). Source data are available for this figure.

Article Snippet: To inhibit the polycomb repressive complex 2 protein, we used a specific chemical inhibitor to EZH2 called GSK126 (Cat. No. 6790; Tocris).

Techniques: Quantitative RT-PCR, Western Blot, Control, Inhibition

Review

ezh2 inhibitor gsk 126 (MedChemExpress)

Structured Review

Images

Related Articles

Concentration Assay:

Isolation:

Cell Isolation:

Methylation:

Similar Products

Image Search Results